Document is current
Any future updates will be listed below
-
Authors
Takei, Shota
Shiono, Ayako
Yamasaki, Satoshi
Yamaguchi, Ou
Mouri, Atsuto
Miura, Yu
Hashimoto, Kosuke
Imai, Hisao
Kaira, Kyoichi
Kagamu, Hiroshi
-
Funding
Funding for this research was provided by:
KAKENHI program of the Japan Society for the Promotion of Science grant, Japan Agency for Medical Research and Development grant
- License Information
-
More Information
Article History
Received: 29 August 2025
Accepted: 16 November 2025
First Online: 19 December 2025
Declarations
:
: OY reports personal fees from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical Company Limited, Nippon Kayaku, Daiichi Sankyo, MSD, Novartis Pharma K.K., Kyowa Kirin Co., Ltd., Amgen K.K., and Janssen Pharmaceutical K.K. KK reports personal fees from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and AstraZeneca and research grants from AstraZeneca. HK reports personal fees from Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, Chugai Pharmaceutical Co., AstraZeneca, MSD, and research grants from Boehringer Ingelheim, Chugai Pharmaceutical Co., Nippon Kayaku. No disclosures were reported by the other authors.
: The study protocol was approved by the Institutional Review Board of Saitama Medical University International Medical Center in accordance with the Declaration of Helsinki (approval number: 16–281).
: All participants provided written informed consent.
